Botulinum toxin field assays evaluated using cosmetic botox preparations.
Several quick tests for identifying botulinum toxins (BoNTs) are commercially available, but generally these tests have not been evaluated by independent laboratories. This study presents data on the evaluation of a number of commercial tests and demonstrates the use of cosmetic preparations of BoNT A and B as positive controls. For reference we used an in-house ELISA procedure. The cosmetic toxins, Botox(®) and Neurobloc(®), were found to be useful-that is, they had a sufficiently high toxin content to be used in test evaluation studies. Some commercial kits based on columns (ABICAP(®)) or lateral flow technology were tested for their detection limits. The ABICAP column system was found to be a useful alternative to an in-house ELISA method. In general, the lateral flow-based test systems evaluated here were not able to detect BoNT, and a large proportion of the tests showed construction failures. In conclusion, this study showed that cosmetic BoNT products have enough toxin content to be used as convenient and accessible means of testing commercially available quick tests. The lateral flow tests used in this study were not satisfactory, while the ABICAP system was found to be a good alternative to an ELISA.
Hans-Christian
HC
Slotved
Julia Tanas
JT
Tanassi
Nadja
N
Sparding
Anja
A
Lindqvist
Nina R
NR
Steenhard
Niels H H
NH
Heegaard
D001905:Botulinum Toxins / Q000032:analysis*; D019274:Botulinum Toxins, Type A / Q000032:analysis*; D002846:Chromatography, Affinity; D003358:Cosmetics / Q000737:chemistry*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D012015:Reference Standards
D003358:Cosmetics; D011933:Reagent Kits, Diagnostic; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A